Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV)

Antiviral Res. 1997 Jan;33(2):87-97. doi: 10.1016/s0166-3542(96)01004-2.

Abstract

Prostratin, a non-tumor-promoting phorbol ester, inhibited human immunodeficiency virus (HIV)-induced cell killing and viral replication in a variety of acutely-infected cell systems. The potency and degree of cytoprotection was dependent on both viral strain and host cell type. Prostratin activated viral expression in two latently-infected cell lines, but had little or no effect on chronically-infected cell lines. Prostratin caused a dose-dependent, but reversible, decrease in CD4 expression in the CEM-SS and MT-2 cell lines. This down-regulation of CD4 was inhibited in a dose-dependent manner by the protein kinase C (PKC) antagonist, staurosporine. In addition, the cytoprotective and cytostatic effects of prostratin in CEM-SS cells acutely infected with HIV-1RF were reversed by bryostatin-1, a PKC agonist. Prostratin had no effect on reverse transcriptase or HIV-1 protease, nor did it inhibit the binding of gp120 to CD4. We conclude that prostratin inhibits HIV cytopathicity and replication through mechanism(s) involving PKC enzyme(s).

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Bryostatins
  • CD4 Antigens / metabolism
  • Cell Line
  • Cell Line, Transformed
  • Cytopathogenic Effect, Viral / drug effects
  • Down-Regulation
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • Humans
  • Lactones / pharmacology
  • Macrolides
  • Phorbol Esters / pharmacology*
  • Virus Replication / drug effects

Substances

  • Anti-HIV Agents
  • Bryostatins
  • CD4 Antigens
  • Lactones
  • Macrolides
  • Phorbol Esters
  • bryostatin 1
  • prostratin